Spondylitis, Ankylosing Clinical Trial
Official title:
Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis
The objective of this study is to prove reasonability of registration in Russian federation this new indication (ankylosing spondylitis [AS]) through evaluation of safety and efficacy rate of Remicade 5mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01208207 -
A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)
|
Phase 3 | |
Completed |
NCT02509026 -
Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA
|
Phase 4 | |
Completed |
NCT02704845 -
Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain
|
N/A | |
Terminated |
NCT01209702 -
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
|
Phase 3 | |
Terminated |
NCT01209689 -
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
|
Phase 3 | |
Terminated |
NCT00766402 -
An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)
|
Phase 4 | |
Completed |
NCT00000433 -
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis
|
Phase 2 | |
Completed |
NCT00779935 -
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
|
Phase 4 | |
Completed |
NCT01863732 -
Extension in AS: Sustainability of Benefits, Safety and Tolerability
|
Phase 3 | |
Recruiting |
NCT05879419 -
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
|
Phase 4 | |
Completed |
NCT01567878 -
Ultrasound of Enthesis in Patients With Ankylosing Spondylitis: a Comparative Study With Health Subjects
|
N/A | |
Completed |
NCT01188655 -
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
|
N/A | |
Completed |
NCT00760669 -
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
|
Phase 4 | |
Completed |
NCT02159053 -
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis
|
Phase 3 | |
Completed |
NCT00202865 -
Evaluation of Low Dose Infliximab in Ankylosing Spondylitis (Study P04352)
|
Phase 3 | |
Completed |
NCT02374502 -
Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial
|
N/A | |
Terminated |
NCT00273858 -
Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis
|
N/A | |
Withdrawn |
NCT00298012 -
Methotrexate in the Treatment of Axial Spondyloarthritis
|
Phase 4 | |
Completed |
NCT04810715 -
Frequency of Pes Planus and Posterior Tibial Tendon Dysfunction in Patients With Ankylosing Spondylitis
|
||
Completed |
NCT03880968 -
Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis
|